- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.08. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| ELUTIA Aktie jetzt für 0€ handeln | |||||
| 18.08. | Elutia Flat on Sale to Cellution | 1 | Baystreet.ca | ||
| 18.08. | Elutia sells SimpliDerm business for up to $11 million | 2 | Investing.com | ||
| 18.08. | Elutia Inc.: Elutia Completes SimpliDerm Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch | 3 | GlobeNewswire (USA) | ||
| 14.08. | ELUTIA INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 14.08. | Elutia anticipates NXT-41x clearance in 1H 2027 while targeting >80% gross margins at scale | 1 | Seeking Alpha | ||
| 14.08. | Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch | 1 | Investing.com | ||
| 14.08. | Elutia Q2 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 13.08. | Elutia GAAP EPS of -$0.17 misses by $0.02, revenue of $2.4M misses by $0.5M | 1 | Seeking Alpha | ||
| 13.08. | Elutia sichert sich 26 Mio. USD Kapital vor wichtiger FDA-Entscheidung | 2 | Investing.com Deutsch | ||
| 13.08. | Elutia secures $26M in capital, expects FDA decision on NXT-41 | 1 | Investing.com | ||
| 13.08. | Elutia secures $15 million financing for product development | 1 | Investing.com | ||
| 13.08. | Elutia Inc.: Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results | 164 | GlobeNewswire (Europe) | Funded through launch: secured up to $26 million of capital without an equity offeringThe unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection riskThe demand... ► Artikel lesen | |
| 07.08. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.07. | Elutia Inc.: Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 | 1 | GlobeNewswire (USA) | ||
| 20.07. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.07. | Elutia Sheds Legacy Business to Chase $1.5 Billion Market Opportunity | 3 | Benzinga.com | ||
| 17.07. | Elutia To Divest SimpliDerm Business For Up to $11 Million | 1 | pulse2.com | ||
| 16.07. | Elutia to sell SimpliDerm business for up to $11 million | 1 | Investing.com | ||
| 16.07. | Elutia Inc.: Elutia Signs Definitive Agreement to Sell SimpliDerm in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch | 151 | GlobeNewswire (Europe) | Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 monthsProceeds provide additional non-dilutive capital... ► Artikel lesen |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Personalentscheidungen / Vorstand/Strategische Unternehmensentscheidung
QIAGEN N.V.: QIAGEN ernennt Jonathan M. Pratt zum Vorstandsvorsitzenden... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 23,780 | 0,00 % | Here's Why You Should Add ARQT Stock to Your Portfolio Now | ||
| HARMONY BIOSCIENCES | 39,210 | 0,00 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| ERASCA | 18,040 | +0,06 % | Erasca, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 134,97 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,670 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Potenzial trotz Mega-Rallye: Merck & Co. nach 40-%-Rallye: Morgan Stanley zündet den Kursziel-Turbo! | © Foto: Rafael Henrique - SOPA Images via ZUMA Press WireDie Aktie von Merck Sharp & Dohme (MSD) ist 2026 bereits 40 Prozent gestiegen. Doch Morgan Stanley hebt das Kursziel massiv an - und erklärt... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 345,01 | +0,08 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,760 | -0,05 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,08 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,210 | +0,06 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,370 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,770 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen |
Das Unternehmen ELUTIA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,880 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELUTIA INC finden Sie auf Wallstreet Online.